OPKO Health (NASDAQ:OPK) Receives Sell (D-) Rating from Weiss Ratings

Key Points

• OPKO Health's stock has been assigned a dismal “sell (D-) rating” by Weiss Ratings, despite some other analysts providing more favorable assessments.
• The company reported a loss of ($0.19) per share in its recent quarterly earnings, missing analysts' expectations and showing a 13.9% decline in revenue year-over-year.
• Institutional investors currently hold 64.63% of OPKO Health's stock, indicating strong interest from larger financial entities in the company.

OPKO Health (NASDAQ:OPK - Get Free Report)'s stock had its "sell (d-)" rating reissued by research analysts at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

A number of other research analysts also recently commented on OPK. Zacks Research raised OPKO Health from a "strong sell" rating to a "hold" rating in a research note on Thursday, August 14th. LADENBURG THALM/SH SH upgraded OPKO Health to a "strong-buy" rating in a report on Tuesday, July 8th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $2.63.

OPKO Health Stock Up 0.6%

Shares of NASDAQ:OPK opened at $1.55 on Wednesday. OPKO Health has a 12 month low of $1.11 and a 12 month high of $2.04. The company's 50-day moving average price is $1.40 and its two-hundred day moving average price is $1.39. The company has a quick ratio of 3.02, a current ratio of 3.41 and a debt-to-equity ratio of 0.25. The firm has a market cap of $1.23 billion, a P/E ratio of -6.20 and a beta of 1.50.

OPKO Health (NASDAQ:OPK - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The biotechnology company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.07). The firm had revenue of $156.80 million during the quarter, compared to analyst estimates of $165.74 million. OPKO Health had a negative net margin of 26.68% and a negative return on equity of 13.17%. The business's revenue was down 13.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.01) earnings per share. As a group, research analysts forecast that OPKO Health will post -0.25 EPS for the current fiscal year.

Insider Activity

In related news, CEO Phillip Md Et Al Frost bought 675,000 shares of the stock in a transaction that occurred on Friday, August 8th. The shares were bought at an average cost of $1.32 per share, for a total transaction of $891,000.00. Following the completion of the transaction, the chief executive officer owned 214,676,448 shares of the company's stock, valued at approximately $283,372,911.36. This trade represents a 0.32% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 49.69% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of OPKO Health by 75.3% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company's stock valued at $42,000 after purchasing an additional 12,417 shares during the last quarter. Pallas Capital Advisors LLC acquired a new stake in OPKO Health in the 1st quarter worth about $43,000. SG Americas Securities LLC acquired a new stake in OPKO Health in the 1st quarter worth about $585,000. Assenagon Asset Management S.A. lifted its stake in OPKO Health by 9.1% in the 1st quarter. Assenagon Asset Management S.A. now owns 935,100 shares of the biotechnology company's stock worth $1,563,000 after purchasing an additional 78,362 shares in the last quarter. Finally, PFG Investments LLC raised its position in shares of OPKO Health by 4.9% during the 1st quarter. PFG Investments LLC now owns 1,217,360 shares of the biotechnology company's stock valued at $2,021,000 after buying an additional 56,475 shares during the period. Institutional investors own 64.63% of the company's stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.